Metabolomics analysis and algorithmically constructed metabolic networks hinted that AKT and LDLR are involved in THF's pharmaceutical effects, and qPCR and Western blotting results supported the hypothesis that THF improves glucose intolerance and hepatosteatosis in DIO rats by potentially targeting AKT-SREBP nexus. Here, AKT1 is linked to Glucose intolerance.